PLBD1-AS1: A Potential Drug Target and Biomarker (G101928290)

Target Name: PLBD1-AS1

NCBI ID: G101928290

PLBD1-AS1

Other Name(s): PLBD1 antisense RNA 1

PLBD1-AS1: A Potential Drug Target and Biomarker

PLBD1-AS1, also known as PLBD1 Antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression patterns make it an attractive candidate for further research and development as a new drug or diagnostic biomarker.

ThePLBD1 gene is located on chromosome 6 and encodes a protein known as PLBD1, which is a key regulator of cell proliferation and survival. PLBD1 has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. It has also been implicated in the development and progression of various diseases, including cancer.

To better understand the role of PLBD1 in disease, researchers have studied its expression patterns in various organisms, including humans. Studies have shown that PLBD1 is highly expressed in various tissues and organs, including the brain, pancreas, and gastrointestinal tract. It is also expressed in various types of cancer, including breast, ovarian, and colorectal cancer.

One of the key features of PLBD1 is its ability to interact with other molecules in the cell. It has been shown to form complex with various proteins, including the transcription factor, p53. This interaction between PLBD1 and p53 suggests that PLBD1 may play a role in the regulation of p53-mediated cellular processes, including DNA replication, apoptosis, and cell cycle progression.

Another promising aspect of PLBD1 is its potential as a drug target. Its interaction with p53 makes it a potential target for inhibitors that can reduce the level of p53 activity. This is because p53 is a critical regulator of cell growth and apoptosis, and drugs that can inhibit its activity have been shown to be effective in various diseases, including cancer.

Research has also shown that PLBD1 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that PLBD1 may be a useful biomarker for these diseases, as well as for other types of cancer.

In addition to its potential as a drug target, PLBD1 also has the potential as a biomarker. Its expression patterns have been shown to be altered in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that PLBD1 may be a useful biomarker for these diseases, as well as for other types of cancer.

To further study the potential of PLBD1 as a drug target and biomarker, researchers are currently conducting various studies to investigate its effects on cancer cell growth, apoptosis, and other cellular processes. They are also exploring the use of various techniques, including RNA interference and CRISPR/Cas9 genome editing, to modulate its expression levels and study its potential interactions with other molecules in the cell.

In conclusion, PLBD1-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression patterns make it an attractive candidate for further research and development as a new drug or diagnostic biomarker. Further studies are needed to fully understand its role in disease and its potential as a drug target and biomarker.

Protein Name: PLBD1 Antisense RNA 1

The "PLBD1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLBD1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets